VP Lung Cancer Flashcards

1
Q

_____ most common UK cancer and most common worldwide

A

Second

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Aetiology:

  • Smoking is the biggest cause (around __% of cases)
  • Period of time smoking is __ important than number of cigarettes smoked
  • Around 1/6 lifelong smokers ___ of lung cancer
  • Stop smoking and immediately reduce risk and after __years the risk of developing as the same as a non smoker
A

90%
More
Die
15 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Risk factors:

  • Smoking
  • ____ smoking
  • History of previous lung disease
  • _____ exposure
  • _____ gas exposure
A

Passive
Asbestos
Radon gas exposure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pathology SCLC:

  • Around ___% of cases
  • ___, ___ cells
  • ____ tumour
  • Surgery has a ____ role
  • Usually ____ when diagnosed
  • Responds ____ to chemo and radiation

NSCLC:

  • Around __% of cases
  • Several types: squamous cell, ______ and large cell
  • Surgery if caught early
  • Metastasises to ___, ____ and bones
  • ____ responsive to chemo
A
15% 
Small, uniformed
Aggressive 
Limited
Metastatic 
Well 

85%
Adenocarcinoma
Brain, liver and bones
Less responsive to chemo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Clinical presentation:

  • No symptoms at early stage but then: _____, _____-____, ____, ____ and _____ pain
  • Symptoms are usually due to tumour ____/_____.
  • Smokers cough, persistent, ___, ____ and dyspnoea
  • _____ - coughing up blood - significant symptom
  • Over __% have metastatic disease at presentation
  • Early disease often confused with ___ (similar symps)
  • Early disease often diagnosed during routine chest _-__
A
Fatigue, weight loss, back, neck and shoulder pain 
Pressure/obstruction 
wheezing/SOB
Haemoptysis 
50%
COPD
X-RAY
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Diagnostic tests:

  • Chest _-___
  • B_______ (stick tube into lung and remove lump to _____)
  • Sputum _____ (often cancer cells in sputum)
  • __ scan (assess suitability for surgery and assess sites of common metastases e.g. _____)
  • Lung _____ tests to establish baseline condition
A
Chest X-RAY
Bronchoscopy - so can biopsy tumour 
Sputum cytology
CT scan and sites of common metastases e.g. liver
Lung function tests
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Staging of cancer:

  • description of extent of cancer ____
  • ___ of tumour
  • How deeply it _____
  • Whether it invaded adjacent or _____ organs
  • How many ____ ____ it spread to (if any)
  • Treatment usually determined by staging
  • ___ staging is also used
A
Spread
Size
Penetrated
Distant 
Lymph nodes

TNM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

SCLC:

1) Limited stage disease (__%)
- Cancer confined to one side of ____ and involves ____ ____
- Can be treated using _____

2) _____ stage disease (__%)
- Cancer ______ to distant organs

A

30%
Chest
Lymph nodes
Radiotherapy

Extensive
70%
Metastasised

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Treatment of SCLC:
Limited stage:
5% - _____ then ____ chemo
Others - _______ and _____

Extensive stage:
________ chemotherapy

A

Surgery then adjuvant chemo
Radiotherapy and chemotherapy

Palliative chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Treatment of NSCLC: (4 options)

A

1) Surgery (cure)
2) Radiotherapy (cure)
3) Radiofrequency abalation (if not fit enough for surgery)
4) 1st line chemo/targeted Tx for advanced or metastatic NSCLC - then maintenance chemo and then 2nd line chemo/targeted treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Surgery in NSCLC:

  • Only NSCLC stage _ or _ - disease might be _a when tumour shrunk by chemo first
  • ____ - most common - removal of entire ____ of lung affected by tumour
  • ______ - remove entire lung - high _____ rates and long term debility only if good ___ performance status pre op
  • Major complications occur in 30% undergoing surgery for LC
A
1 or 2
3a
Lobectomy 
Lobe
Pneumonectomy 
Mortality 
WHO
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Adjuvant chemotherapy in NSCLC:

  • Given post ____ to eradicate cells that were not removed - use a ______ based chemo regimen
  • Offered to those with good ___ performance status
A

Surgery
Cisplatin
WHO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Treatment of advanced/metastatic NSCLC:

  • With stage - NSCLC and good ___ performance status
  • Encourage smoking _____ (can interact with some drugs)
  • Treatment depends on specific tumour subtype ______ either _______ or _____ ___ carcinoma
  • Also depends on biomarkers/mutations e.g. ____ mutation or ___ (anapaestic lymphoma kinase) gene _____.
A
3-4
WHO 
Cessation 
Histology 
Adenocarcinoma or squamous cell carcinoma 
EGFR mutation or ALK gene translocation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Treatment example of NSCLC adenocarcinoma with ALK translocation:
C_____ = treatment of choice
- Oral ___ receptor inhibitor
- Taken continuously until ____ _____/toxicity

Side effects: (6)

A

Crizotinib
ALK (anaplastic lymphoma kinase)
Disease progression

Visual problems (photophobia, blurred vision, diplopida)
Nausea and vom, diarrhoea
Oedema (face and general)
Neuropathy
Neutropenia
Interstitial lung disease (inflam disease of interstitium in lungs - important for supporting alveoli - if thickens then gas xchange poor and coughing occurs. Hard to treat so monitor for signs and phone after 1 week and quiz on any side effects. If coughing and SOB then get back in to monitor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Treatment example of adenocarcinoma without ___ or EGFR mutation:
____/____ chemotherapy for 4-6 cycles
Both _____ and _____ on day one (IV infusions)
__ day cycles
Then maintenance _____ until disease progression/toxicity
- Median overall survival __ months (11 w/o pemetrexed maintenance dose)

Side effects: (8)

A
ALK (anaplastic lymphoma kinase) 
Cisplatin/pemetrexed
Cisplatin/pemetrexed
28 day cycles
Pemetrexed
14 months 
Nausea and vomiting
Diarrhoea
Stomatitis
Alopecia 
Peripheral neuropathy (cisplatin) 
Ototoxicity 
Nephrotoxicity (monitor renal function) 
Myelosuppression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Pharmaceutical care issues regarding Pemetrexed and Cisplatin regime when treating NSCLC adenocarcinoma without EGFR/ALK mutations:

  • Check ___ and dose
  • Measure ___, ____ function (must be over 55ml/min)
  • Ensure _______ are Rx
  • Ensure pre and post _____ is prescribed (Before and after Cisplatin)
  • Ensure ____ output of 100ml or more during and for 6-8hrs post cisplatin
  • Patients may need additional _____ if urine output inadequate/weight gain (____ retention)
  • Monitor pt for cisplatin induced wasting of electrolytes - ____ may be needed

Pemetrexed is an _____ agent so to reduce toxicity premedicate with Vit ___ and ____ ____. To reduce pemetrexed skin reactions give ________ (steroid) orally for 3 days. Start the day before chemo.

A
BSA and dose
FBC, renal 
Antiemetics
Hydration 
Urine 
Diuresis 
Fluid retention 
Supplements e.g. Mg, Ca, K

Antifolate
Vit B12 and folic acid
Dexamethasone

17
Q

Squamous cell carcinoma with EGFR mutation treatment:
G_____ (I_____), E____ (T_____), A_____ = options
- All oral TKIs (_____ _____ _____) that target the _____-__.
It blocks the _____-__ to help slow growth and spread of cancer by inhibiting signal ____.
Afatinib was approved by NICE in 2014 for locally advanced/metastatic NSCLC which is ____ mutation _ve.

A

Gefitinib (Iressa), Erlotinib (tarceva), Afatinib

  • Tyrosine kinase inhibitors
  • EGFR-TK
  • EGFR-TK
  • Transduction
  • EGFR mutation +ve
18
Q

Afatinib (Giotrif)

  • Compared to chemo in patients with EGFR mutation progression free survival was 11.1 months compared to treatment with chemo 6.9 months.
  • But side effects (5) what are they?
A
Diarrhoea
Stomatisis
Skin reactions (acne like rash, erythema)
Hepatotoxicity (increase LFTs)
Paronychia
19
Q

Pembrolizumab - NICE approved for PD-L1 +ve NSCLC after chemo IF:

  • Pembrolizumab stopped at _yrs of uninterrupted treatment and no documented disease progression
  • Also need to get at agreed _____ price.
  • Adverse reactions: (9)
  • Ev 3 weeks until _____ _____ or unacceptable _____.
  • Humanised _____ ____ bind to PD-1R (_____ ___ ____ _ ____) and blocks it’s interaction with ligands. It increases _ cell responses.
A

2yrs
Discounted
Fatigue, decreased appetite, nausea, rash and pruritus, anaemia, pneumonitis, arthralgia, immune related disorders (hepatitis, nephritis, colitis)
Disease progression or unacceptable toxicity
Humanised monoclonal antibody
Programmed cell death 1 receptor)
T cell

20
Q

SO SCLC ___ responsive to chemo than NSCLC. SCLC has a ____ prognosis. NSCLC usually requires _____ therapy.

A

More
Poor
Targeted